|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SNTA1 |
Gene summary for SNTA1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SNTA1 | Gene ID | 6640 |
| Gene name | syntrophin alpha 1 | |
| Gene Alias | LQT12 | |
| Cytomap | 20q11.21 | |
| Gene Type | protein-coding | GO ID | GO:0001508 | UniProtAcc | Q13424 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 6640 | SNTA1 | male-WTA | Human | Thyroid | PTC | 1.18e-24 | 1.90e-01 | 0.1037 |
| 6640 | SNTA1 | PTC01 | Human | Thyroid | PTC | 2.07e-07 | 1.13e-02 | 0.1899 |
| 6640 | SNTA1 | PTC04 | Human | Thyroid | PTC | 3.24e-04 | 1.32e-01 | 0.1927 |
| 6640 | SNTA1 | PTC05 | Human | Thyroid | PTC | 1.34e-12 | 2.80e-01 | 0.2065 |
| 6640 | SNTA1 | PTC06 | Human | Thyroid | PTC | 3.49e-13 | 2.46e-01 | 0.2057 |
| 6640 | SNTA1 | PTC07 | Human | Thyroid | PTC | 1.93e-18 | 1.55e-01 | 0.2044 |
| 6640 | SNTA1 | ATC09 | Human | Thyroid | ATC | 1.58e-08 | 3.37e-01 | 0.2871 |
| 6640 | SNTA1 | ATC12 | Human | Thyroid | ATC | 1.73e-15 | 1.24e-01 | 0.34 |
| 6640 | SNTA1 | ATC13 | Human | Thyroid | ATC | 6.95e-10 | 1.81e-02 | 0.34 |
| 6640 | SNTA1 | ATC1 | Human | Thyroid | ATC | 1.15e-08 | 3.70e-01 | 0.2878 |
| 6640 | SNTA1 | ATC4 | Human | Thyroid | ATC | 5.00e-15 | 1.43e-01 | 0.34 |
| 6640 | SNTA1 | ATC5 | Human | Thyroid | ATC | 1.23e-05 | 2.67e-02 | 0.34 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00508089 | Thyroid | PTC | synapse organization | 161/5968 | 426/18723 | 5.11e-03 | 2.36e-02 | 161 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SNTA1 | SNV | Missense_Mutation | c.1513N>T | p.Ala505Ser | p.A505S | Q13424 | protein_coding | deleterious(0.01) | probably_damaging(0.994) | TCGA-A2-A0CV-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |
| SNTA1 | deletion | In_Frame_Del | novel | c.765_782delNNNNNNNNNNNNNNNNNN | p.Ser256_Ala261del | p.S256_A261del | Q13424 | protein_coding | TCGA-A2-A3XZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR | ||
| SNTA1 | deletion | Frame_Shift_Del | novel | c.985delN | p.Glu329ArgfsTer6 | p.E329Rfs*6 | Q13424 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| SNTA1 | deletion | Frame_Shift_Del | novel | c.1383delN | p.Ser462ValfsTer25 | p.S462Vfs*25 | Q13424 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
| SNTA1 | deletion | Frame_Shift_Del | novel | c.870delN | p.Ser291AlafsTer10 | p.S291Afs*10 | Q13424 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
| SNTA1 | SNV | Missense_Mutation | rs149126874 | c.1007N>A | p.Arg336Gln | p.R336Q | Q13424 | protein_coding | tolerated(0.16) | benign(0) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| SNTA1 | SNV | Missense_Mutation | rs775740746 | c.590N>A | p.Arg197Gln | p.R197Q | Q13424 | protein_coding | tolerated(0.56) | benign(0) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| SNTA1 | SNV | Missense_Mutation | c.734N>G | p.Asp245Gly | p.D245G | Q13424 | protein_coding | tolerated(0.4) | benign(0.006) | TCGA-C5-A1BE-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD | |
| SNTA1 | SNV | Missense_Mutation | c.1469T>A | p.Ile490Asn | p.I490N | Q13424 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-C5-A1ML-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD | |
| SNTA1 | SNV | Missense_Mutation | novel | c.1480N>A | p.Leu494Met | p.L494M | Q13424 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-VS-A8QH-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | gemcitabine | PD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |